GLP-1 Gold Rush: The $100B Healthcare Market Growing 10% Yearly

Good morning, ! This week we’re diving into the 10% annual growing market of GLP-1 and it`s main players. Multiagent AI is gaining share in Healthcare technology. Outdated provider data now triggers compliance payment and audit risks.

Want to advertise in Healthcare 150? Check out our ad platform, here.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

DATA DIVE

The $100B Weight Loss Trade

GLP-1 drugs have quietly turned into healthcare’s most crowded trade—and the numbers back it up. The market is projected to grow from $52.9B in 2025 to $132.8B by 2035, a near 10% CAGR that feels more infrastructure than hype.

What changed? Obesity became investable.

Patient growth tells the story: U.S. adoption is expected to jump from 5.2M in 2023 to 30.3M by 2030, with ~65% tied to obesity, not diabetes.

The kicker: this isn’t just a pharma boom. It’s a payer dilemma. Short-term costs spike, long-term savings (cardio, metabolic) remain probabilistic.

Bottom line: GLP-1s aren’t a category—they’re becoming a cost-containment strategy disguised as a drug class. (More)

HEALTHTECH CORNER

Healthcare AI Splits Into Two Markets

Multiagent AI is gaining traction in healthcare, but the chart suggests buyers are separating into very different procurement paths. Among payers, 41% favor end to end workflow automation with multiagent systems, the highest across surveyed subsectors. That is a strong signal that insurers see immediate value in automating claims, prior authorization, member services, and other rules-based processes where ROI can be measured quickly.

Clinical care organizations are taking a narrower route. 59% prefer focused, function-specific solutions, while only 29% favor full workflow automation. Hospitals appear interested in AI, but still cautious about handing mission-critical workflows to broader autonomous systems. Integration complexity, clinician trust, and regulatory exposure likely remain the gating factors.

Health services and technology companies sit somewhere else entirely. 48% prioritize common cross-cutting use cases, suggesting horizontal tools such as coding, documentation, analytics, and customer operations may scale faster than bespoke agent stacks.

Why this matters now: 2026 may not be the year of one healthcare AI winner. It may be the year the market fragments into payer automation leaders, provider point-solution specialists, and horizontal enablement platforms. Capital should follow whichever segment can prove implementation speed and measurable savings first. (More)

PRESENTED BY EXACT INSIGHT

95%+ Qualified Respondents Start With a Better Research Process.

Private equity teams do not struggle to find information. They struggle to trust it.

When a deal is live, weak respondent quality can create false confidence, wasted diligence cycles, and more work for teams already moving at speed. Traditional expert networks can help firms access conversations, but access alone does not guarantee quality, repeatability, or decision-ready research. By contrast, Exact Insight is built around 95%+ qualification rates, helping firms start with stronger inputs from the beginning.

That matters even more when timelines are compressed and teams are expected to move from initial diligence to sharper thesis validation without slowing down. If the inputs are inconsistent or difficult to verify, speed quickly becomes a liability rather than an advantage.

That is why more firms are raising the bar on the data behind their diligence. Better decisions start with better inputs.

See How Exact Insight Improves Research Quality →

COMPLIANCE CORNER

If It Isn’t Documented, It Didn’t Happen

CMS is making a subtle but important point in 2026: sloppy data is no longer an administrative nuisance — it’s a compliance event.

Under the latest Conditions of Participation (CoPs) enforcement priorities, regulators are zeroing in on data accuracy, timely reporting, and documentation fidelity. Providers now face strict 30-day windows to update ownership changes, legal actions, and practice locations in PECOS and related systems. Miss the deadline, and the risk extends beyond embarrassment.

Why? Because stale data increasingly flows downstream into payment eligibility, risk-adjusted reimbursement, quality scores, and patient outcome measures like STAR ratings. In other words, the spreadsheet now sits closer to the bedside than many executives realize.

Meanwhile, infection control and staffing remain evergreen enforcement themes, even without flashy new rulemaking.

Bottom line: Treat provider data like clinical data — governed, current, and audit-ready. In healthcare compliance, yesterday’s outdated address can become tomorrow’s denied payment. (More)

COMPETITIVE LANDSCAPE SNAPSHOT

TREND TO WATCH

Healthcare’s Affordability Crisis Is Becoming a Utilization Crisis

The U.S. healthcare debate often centers on coverage. The more immediate issue is whether insured patients can actually afford to use that coverage. Rising premiums, deductibles, and pharmacy costs are eroding the practical value of insurance, pushing more households to delay care, ration prescriptions, or skip treatment entirely.

That distinction matters. When patients defer routine management of diabetes, hypertension, or obesity, costs do not disappear. They compound into higher-acuity admissions, more complex interventions, and worse outcomes later. What looks like consumer cost-sharing today becomes medical loss inflation tomorrow.

The pressure is spreading beyond the uninsured. As employers continue shifting benefit costs to workers, the traditional employer-sponsored model risks a credibility problem: coverage that exists on paper but fails at point of care. That creates openings for lower-cost care delivery models, transparent pharmacy platforms, supplemental benefits, and navigation tools that reduce out-of-pocket friction.

Why this matters now: investors and operators should watch utilization patterns, medication adherence, and deferred elective volumes more closely than enrollment figures. The next healthcare squeeze may not come from losing coverage. It may come from patients keeping coverage and avoiding care anyway. (More)

"Whenever you see a successful business, someone once made a courageous decision."

Peter Drucker